Trillium Therapeutics Revenue, Profits - TRIL Quarterly Income Statement

Add to My Stocks
$6.25 $0.05 (0.79%) TRIL stock closing price Sep 17, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Trillium Therapeutics stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement for TRIL which shows a YOY revenue decline of 0 is specific to a period of time. Investors typically check YoY or QoQ revenue growth. Revenue for year 2018 Q2 is $- and has decreased from $- quarter on quarter as is evident when you compare the latest figures in the latest Trillium Therapeutics profit and loss statement with those of the prior corresponding period. Also see Trillium Therapeutics assets and Trillium Therapeutics free cash flow for a complete valuation of TRIL stock.

View and download details of revenue and profits for Trillium Therapeutics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Trillium Therapeutics Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
Trillium Therapeutics Gross Profit
----------
Research & Development Expense9.86M7.39M7.76M6.6M6.58M7.7M6.94M5.92M4.98M4.65M
Selling General & Admin Expense----------
Income Before Depreciation Depletion Amortization-10.83M-8.2M-8.74M-7.37M-7.09M-8.42M-7.63M-6.71M-5.72M-5.4M
Depreciation Depletion Amortization----------
Non Operating Income1.29M1.43M--1.65M-1.55M-0.2M-2.01M---
Interest Expense-------2.8M--2.6M
Trillium Therapeutics Pretax Income
-9.54M-6.77M-8.43M-9.04M-8.65M-8.65M-6.87M-6.05M-5.89M-7.93M
Provision for Income Taxes-------0.09M---2.68M
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-9.54M-6.78M-8.39M-9.05M-8.66M-8.65M-9.52M-6.06M-5.9M-5.07M
Extraordinary Items & Discontinued Operations----------
Trillium Therapeutics Profit/ Loss (Net Income)
-9.54M-6.78M-8.39M-9.05M-8.66M-8.65M-9.52M-6.06M-5.9M-5.07M
Average Shares used to compute Diluted EPS13.39M13.18M11.71M10.8M8.29M7.84M8.72M7.82M7.82M4.01M
Average Shares used to compute Basic EPS13.39M13.18M11.71M10.8M8.29M7.84M8.72M7.82M7.82M4.01M
Income Before Nonrecurring Items-9.55M-6.78M-8.39M-9.05M-8.66M-8.65M-9.52M-6.06M-5.9M-5.07M
Income from Nonrecurring Items----------
Trillium Therapeutics Earnings Per Share Basic Net
-0.71-0.51-0.72-0.84-0.99-1.10-0.86-0.78-0.75-1.26
Trillium Therapeutics Earnings Per Share Diluted Net
-0.71-0.51-0.72-0.84-0.99-1.10-0.86-0.78-0.75-1.26
EPS Diluted Before Nonrecurring Items-0.71-0.51-0.72-0.84-0.99-1.10-0.86-0.78-0.75-1.26
Preferred Dividends Acc Pd-0.04M-0.06M--------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Trillium Therapeutics stock analysis are:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this quarter of 2018 Q2. Our Trillium Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: Most businesses like Trillium Therapeutics try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The TRIL financials along with Trillium Therapeutics historical stock prices provide a lot of details about the firm.

Trillium Therapeutics Income Statement - Key Financial Ratios